Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN2480961 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Complement Decay-Accelerating Factor (CD55) antibody
- Antibody type
- Monoclonal
- Description
- Purified
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- BRIC216
- Vial size
- 0.2 mg
Submitted references Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome.
Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.
Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.
Effects of acetate dialysate on transforming growth factor beta 1, interleukin, and beta 2-microglobulin plasma levels.
Liszewski MK, Leung MK, Schraml B, Goodship TH, Atkinson JP
Molecular immunology 2007 Mar;44(7):1559-68
Molecular immunology 2007 Mar;44(7):1559-68
Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.
Loberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ
Neoplasia (New York, N.Y.) 2006 Jan;8(1):69-78
Neoplasia (New York, N.Y.) 2006 Jan;8(1):69-78
Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.
Coyne KE, Hall SE, Thompson S, Arce MA, Kinoshita T, Fujita T, Anstee DJ, Rosse W, Lublin DM
Journal of immunology (Baltimore, Md. : 1950) 1992 Nov 1;149(9):2906-13
Journal of immunology (Baltimore, Md. : 1950) 1992 Nov 1;149(9):2906-13
Effects of acetate dialysate on transforming growth factor beta 1, interleukin, and beta 2-microglobulin plasma levels.
Anderson J, Briefel G, Jones JM, Ryu JH, McGuire M, Yun YP
Kidney international 1991 Dec;40(6):1110-7
Kidney international 1991 Dec;40(6):1110-7
No comments: Submit comment
No validations: Submit validation data